Metoclopramide

Metoclopramide is a commonly prescribed gastrointestinal medication with dual roles as a prokinetic and antiemetic agent. It is particularly effective in treating disorders related to delayed gastric emptying and persistent nausea or vomiting. As a dopamine D2 receptor antagonist, Metoclopramide enhances upper gastrointestinal tract motility without affecting acid secretion. Available under brand names such as Maxolon and Reglan, Metoclopramide is used across various healthcare settings—from emergency rooms and hospital wards to general practice and outpatient clinics—highlighting its versatility and clinical value.

Image source Google

Domperidone

 

Comprehensive Clinical Overview of Domperidone

Domperidone is a peripherally selective dopamine D2 and D3 receptor antagonist. It exerts its prokinetic and antiemetic effects predominantly by blocking dopamine receptors in the gastrointestinal (GI) tract and the chemoreceptor trigger zone (CTZ), which lies outside the blood–brain barrier. This unique property greatly reduces the likelihood of central nervous system (CNS) side effects such as sedation and extrapyramidal symptoms.

Clinically, Domperidone is commonly used to manage GI motility disorders and alleviate nausea and vomiting. It enhances coordinated gastric contractions, accelerates gastric emptying, and improves patient tolerance to feeding, particularly in disorders like gastroparesis.

Image source Google

Ondansetron

Uses

Ondansetron, a selective serotonin (5-HT3) receptor antagonist, is widely used for the prevention and treatment of nausea and vomiting. Its primary indications include:

Primary Indications

1. Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV):

   • Effective in both acute and delayed phases of CINV when used alone or in combination with corticosteroids (e.g., dexamethasone).

2. Prevention of Postoperative Nausea and Vomiting (PONV):

   • Used preoperatively or postoperatively to reduce the incidence of nausea and vomiting in patients undergoing surgical procedures.

3. Radiotherapy-Induced Nausea and Vomiting:

   • Prevents nausea and vomiting associated with total body irradiation or high-dose radiotherapy to the abdomen or pelvis.

4. Treatment of Gastroenteritis-Induced Nausea and Vomiting:

   • Commonly used off-label to alleviate nausea and vomiting caused by acute viral or bacterial gastroenteritis, particularly in pediatric and emergency care settings.

5. Hyperemesis Gravidarum (off-label use):

   • Sometimes used in severe cases of pregnancy-induced nausea and vomiting when other treatments are ineffective.

Dosage and Administration

Adults:

1. CINV:

   • Oral: 8 mg 30 minutes before chemotherapy, followed by 8 mg every 12 hours for 1–2 days after chemotherapy.
   • IV: 8–16 mg as a single dose before chemotherapy.

2. PONV:

   • IV: 4 mg as a single dose at induction of anesthesia.
   • Oral: 16 mg taken 1 hour before anesthesia.

3. Radiotherapy-Induced Nausea and Vomiting:

   • Oral: 8 mg 1–2 hours before radiotherapy, followed by 8 mg every 8 hours.

4. Gastroenteritis:

   • Oral or IV: 4–8 mg as needed, depending on severity.

Pediatrics:

1. CINV/PONV:

   • IV: 0.1–0.15 mg/kg (maximum single dose: 4 mg), administered prior to chemotherapy or surgery.
   • Oral: 4 mg for children aged 4–11 years; 8 mg for those aged ≥12 years.

2. Gastroenteritis:

   • Oral: 0.15 mg/kg (maximum single dose: 4 mg).

Presentation

1. Oral Tablets: 4 mg, 8 mg.
2. Oral Disintegrating Tablets (ODT): 4 mg, 8 mg.
3. Oral Solution: 4 mg/5 mL.
4. Injectable Solution: 2 mg/mL, 4 mg/2 mL ampoules.

Mechanism of Action

Ondansetron selectively inhibits serotonin 5-HT3 receptors located:

• In the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS).
• Peripherally in the vagal nerve terminals.

By blocking serotonin’s action, ondansetron prevents the signaling cascade that leads to nausea and vomiting.

Precautions and Safety

1. QT Prolongation:

   • Ondansetron can prolong the QT interval, potentially leading to torsades de pointes.
   • Caution is advised in patients with:
     • Congenital long QT syndrome.
     • Electrolyte imbalances (e.g., hypokalemia, hypomagnesemia).
     • Use of other QT-prolonging drugs (e.g., amiodarone).

2. Hepatic Impairment:

   • Dose adjustment is necessary in severe hepatic impairment (maximum daily dose: 8 mg).

3. Serotonin Syndrome:

   • Rare but serious, especially when combined with other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol). Symptoms include agitation, confusion, tachycardia, hyperreflexia, and diarrhea.

4. Allergic Reactions:

   • Hypersensitivity reactions, including anaphylaxis, are rare but documented.

Side Effects

Common:

• Headache.
• Constipation.
• Dizziness.
• Fatigue or malaise.

Less Common but Serious:

• QT interval prolongation and arrhythmias.
• Serotonin syndrome (when used with serotonergic agents).
• Hypersensitivity reactions (e.g., rash, bronchospasm).

Recent Updates and Guidelines

1. American Society of Clinical Oncology (ASCO) 2023 Guidelines:

   • Recommends the use of ondansetron in combination with neurokinin-1 receptor antagonists (e.g., aprepitant) and corticosteroids for highly emetogenic chemotherapy.

2. National Institute for Health and Care Excellence (NICE) 2022:

   • Supports ondansetron’s off-label use in pediatric gastroenteritis to reduce hospital admissions and improve oral rehydration therapy success rates.

3. FDA Update on QT Prolongation Risk (2020):

   • Reinforces the need for ECG monitoring in high-risk patients receiving ondansetron intravenously, especially at doses exceeding 16 mg.

References

1. National Comprehensive Cancer Network (NCCN) Guidelines: Antiemesis (2023).
2. American Society of Clinical Oncology (ASCO): Antiemetic Guidelines (2023).
3. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (13th Edition).
4. NICE Guidelines: Management of Gastroenteritis in Children (2022).
5. FDA Drug Safety Communication: Ondansetron and QT Prolongation (2020).